Serebellar enfarktli fare modelinde sosyal ve fiziksel zenginleştirilmiş çevrenin sensorimotor ve sosyal performans üzerindeki etkileri

Cerebellar infarction (CI), a rare type of stroke can result in significant motor deficits such as ataxia and gait disorders, impacting daily activities and self-care, potentially leading individuals to experience social isolation. The present study aims to investigate effects of enriched environments as a therapeutic approach for CI in mice, assessing the influence of different environmental factors on the condition. Forty male C57BL/6 mice were divided into 5 groups: physical enrichment, enriched environment, enriched environment +3 healthy mice, standard housing, and sham. The CI model was induced in mice via stereotaxic injection of N5-(1-iminoethyl)-L-ornithine dihydrochloride. Sensorimotor and social performance were assessed pre-infarct and on specific days post-infarct using the wire walk test, footprint test, and three-chamber test. The infarct area was identified by Hematoxylin & Eosin staining. Immunohistochemistry was employed to visualize Biorientation Defective 1 (BOD1), a factor associated with motor coordination, utilizing a confocal microscope. Data were analyzed by two-way ANOVA, with p<0.05 considered significant. CI in mice impacted motor skills, balance, coordination, and social behavior, with subsequent modulation by environmental factors observed longitudinally. The findings underscore the importance of intervention type for post-CI motor recovery. It is demonstrated that motor and cognitive functions, which are related to sociality, are enhanced by physical enrichment and environmental enrichment. However, social enrichment with healthy mice did not provide the same benefits and was linked to continued motor problems. Additionally, overexpression of BOD1, which plays a key role in motor function, was observed in specifics groups. This study uniquely highlights the effects of various enrichment types on motor and sociality-related cognitive processes post-CI and identifies BOD1 as a potential biomarker for effective therapeutic strategies.